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Stimulation of Liver Growth and DNA Synthesis by Glucosylceramide 
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The nature of the growth-stimulating effect of glucosyl- 
ceramide was studied. Mice were injected intraperitw 
neally with emulsified glucosylceramide and conduritol 
B epoxide, an inhibitor of cerebroside glucosidase. Within 
one or two days, the liver grew 18-24%, as reported. Two 
enzymes involved in DNA synthesis also increased more 
than the weight. The total liver activity of thymidine 
kinase increased 46-73%, and the total activity of 
ornithine decarboxylase increased as much as 101%. It 
is suggested that elevated liver levels of glucocerebroside 
stimulate cell proliferation through a relatively direct 
mechanism. 
Lipids 23, 508-510 {1988). 
It is evident that the growth of liver and spleen in 
Gaucher patients, who lack a specific glucohydrolase (EC 
3.2.1.45), is far more than can be accounted for by accom- 
modation to the weight of stored glucosylceramide 
(GlcCer), the enzyme's substrate. The chemical nature of 
the enlarged organs and the mechanisms of the causa- 
tional sequence still are obscure. In a s tudy in which we 
injected mice intraperitoneally over an eight-day period 
with conduritol B epoxide (CBE), an inhibitor of GlcCer 
glucosidase, we found significant increases in liver and 
brain size (9% and 13%, respectively) (1). Presumably, the 
CBE caused an accumulation of the enzyme's substrate 
(2) and, therefore, induced a temporary model form of 
Gaucher disease. In a later study (3), we injected emulsi- 
fied GlcCer once and found that much of the lipid reached 
the liver and that a rapid enlargement of the liver ensued, 
10-37% within 25 hr. Co-injection of CBE with GlcCer 
enhanced the growth phenomenon. The enlargement was 
accompanied by an increase in total DNA, lipid and pro- 
tein {as well as the glucosidase~activator proteins that are 
known to accumulate in Gaucher spleen); it was evident 
that the increase in liver size could not be attributed to 
edema. The detergent alone did not produce a change in 
liver weight. We have postulated that GlcCer can induce 
cell division and growth. The study reported here was 
directed at clarifying the mechanism by which this occurs. 
METHODS AND MATERIALS 
Materials. Most of the materials, the mice used and the 
method for selecting them for each experimental group 
have been described (3,4). The GlcCer, isolated from 
Gaucher spleen, was emulsified with 3/4 of its weight of 
Myrj 52, a low-toxicity nonionic detergent (polyoxyethy- 
lene stearate, ICI America Inc.), and injected i.p. into 
~Current address: Department of Pediatrics, Section of Pediatric 
Neurology, University of Michigan Medical School, Ann Arbor, MI 
48109. 
*To whom correspondence should be addressed at the Neuroscience 
Bldg., 1103 E. Huron, Ann Arbor, MI 48104-1687. 
Abbreviations: CBE, conduritol B epoxide; DTT, dithiothreitol; 
EDTA, ethylenediamine tetraacetic acid; GlcCer, glucosylceramide. 
16-day-old mice (3). Labeled thymidine was from ICN and 
labeled ornithine was from DuPont NEN. 
Assays. Thymidine kinase was measured by following 
the phosphorylation of [3H]thymidine, 182 cpm/nmol, in 
a tube containing Tris-C1- pH 7.5, ethylenediamine tetra- 
acetic acid (EDTA}, mercaptoethanol, adenosine triphos- 
phate (ATPL MgC12, NaF, bovine serum albumin, creatine 
phosphate and creatine kinase {5,6}. The incubation with 
liver cytosol was performed for 30 rain. The resultant 
thymidine phosphate was isolated with ion exchange 
paper. 
Ornithine decarboxylase was measured by following the 
release of [1'C]O2 from L-[1-1'C]ornithine {22.9 cpm]pmol) 
in EDTA, Tris-C1- pH 7.4, DTT, pyridoxal phosphate (7, 
8), and 2-methylornithine (in half of the tubes). Each assay 
tube contained the supernatant suspension from cen- 
trifugation of liver homogenates at 30,000 g for 25 min. 
Protein and DNA were determined as described (3). 
RESULTS 
In one experiment, thymidine kinase specific activity was 
determined in the livers of mice injected with GlcCer/Myrj 
in saline, then (24 hr later} with CBE in saline. A day later, 
the mice were killed, and the livers were analyzed 
(Table 1). Control mice received two injections of saline 
alone. The previous observations, increases in protein and 
DNA that paralleled liver growth, were confirmed. In 
addition, a distinct rise in thymidine kinase total activ- 
ity {46%} was seen. 
In another experiment, GlcCer/Myrj and CBE were in- 
jected as a mixture once, and the animals were killed 24 
or 48 hr later. Thymidine kinase total activity rose 73% 
in 24 hr and subsided to 43% in 48 hr. 
A trial with a single injection of GlcCer/Myrj without 
CBE produced smaller effects, with a 30% increase in 
total enzyme activity after 24 hr. No significant rise was 
seen at seven hr. 
In vitro tests were run to determine whether the addi- 
tion of GlcCer could directly stimulate thymidine kinase. 
Various amounts of GlcCer emulsion {5, 10, 25 and 
50 ~g/ml) in Tris buffer were added to the incubation mix- 
ture just  before the addition of liver enzyme. Incubation 
for 30 or 60 min, with or without GlcCer, produced similar 
observed activities. In an experiment with 50 ~g/ml of 
GlcCer, with and without 5 ~g/ml of phosphatidylserine 
{from bovine brain, Sigma Chemical Co., St. Louis, MO), 
with and without a two-hr preincubation, there was also 
no significant effect of either lipid. However the phospha- 
tidylserine + GlcCer exerted a small inhibitory effect 
{about 12%}. The phospholipid was tested because it is 
an activator of GlcCer glucosidase. 
Another enzyme noted for its responsiveness to various 
growth promoters, ornithine decarboxylase (9), showed 
larger responses in activity to GlcCer and CBE {Table 2). 
This was done as part of the second experiment, above. 
Again, the liver increase in weight was seen, similar at 
the two time points. The total activity of ornithine decar- 
boxylase in the stimulated mouse livers was 101% above 
controls after 24 hr, 64% above after 48 hr. 




Thymidine Kinase Activity in Mice Injected with Glucosylceramide 
Measurement Controls Treated Increase (%) 
Body wt. (g/mouse) 6.70 (0.38) 6.65 (0.27) -0.7 
Liver wt. (rag/mouse} 277 (20) 327 (27) 18 
Protein in liver (rag) 27.6 (1.6) 31.6 (1.1) 14 
DNA in liver (pg) 644 (50) 758 (30) 18 
Thymidine kinase (~moYhr) 1.30 (0.09) 1.90 (0.12) 46 
Nine Hsd CFI mice were injected with GlcCer (250 mg/kg emulsified with Myrj, 188 mg/kg) 
and, a day later, with CBE (80 mg/kg). Saline was injected into nine controls, and all mice 
were killed 24 hr later. The thymidine kinase activity shown is ~nol/hr of thymidine con- 
verted to the monophosphate by the cytosol from one mouse liver, less the blank activi- 
ty from boiled liver. The numbers in parentheses are standard deviations derived from 
six values (duplicates from three groups of three pooled livers) or nine individual values 
in the case of the weights. All increases were statistically significant by Student's t-test 
(p < 0.005). 
TABLE 2 
Ornithine Decarboxylase Activity in Mice Injected with GlcCer and CBE 
Measurement Controls Treated Increase (%) 
Body wt. 24 hr later (g) 6.71 (0.77) 6.78 (0.46) 0 
Body wt. 48 hr later (g) 6.57 (0.66) 6.95 (0.96) 6 
Liver wt. 24 hr (rag) 278 (25) 342 (27) 23* 
Liver wt. 48 hr (rag) 268 (34) 333 (55) 24* 
Ornithine decarboxylase 
24 hr later (nmol]hr) 400 (21) 805 (55) 101" 
48 hr later (nmol/hr) 387 (39) 636 (75) 64* 
*p < 0.005. 
The protocol was similar to that shown in Table 1, but both drugs were injected together 
at time zero, and the animals were killed 24 hr or 48 hr later. Standard deviations are 
shown in parentheses. Decarboxylase activity shown is the amount of ornithine decar- 
boxylated by one liver in one hr, corrected for the blank activity in the presence of decar- 
boxylase inhibitor. 
DISCUSSION 
We have  shown tha t  an emulsion of GlcCer acts  on the 
liver to s t imula te  or increase the amount  of thymidine  
kinase, a major  enzyme of D N A  synthes is  (10). The 
mechanism for the kinase s t im~a t ion  may  not be through 
a direct action on the enzyme, as indicated by  the  lack 
of effect in vitro. However ,  the act ivat ion phenomenon 
m a y  require other  fac tors  t h a t  are needed for in v i t ro  
st imulat ion.  
The increase in ornithine decarboxylase  ac t iv i ty  t ha t  
we observed is consis tent  with the repor ted t w o f o l d  in- 
crease produced by  incubat ing cells wi th  ganglioside, a 
glycolipid derived f rom GlcCer I l l ) .  The incubated 
ganglioside probably  was hydrolyzed in pa r t  to GlcCer, 
and the GlcCer injected into our mice p resumably  was 
conver ted  in pa r t  to ganglioside. I t  remains  to be seen 
which glycolipid or in termedia te  between them was the 
actual  s t imulator .  Ornithine decarboxylase  format ion  is 
induced, generally, by  phorbol  diester, which apparen t ly  
acts  also to s t imulate  phosphoryla t ions  by  a protein 
kinase C 02)  as well as by  a second pa t hway  (9). Bo th  
pa thways  apparent ly  ac t iva te  the format ion of ornithine 
decarboxylase  (13). Gangl iosides  were repor ted  to 
s t imula te  a protein kinase C (14) and to exer t  a pro- 
l iferative action on cells such as neurob las toma (15). 
Phorbol  diester  m a y  act th rough  its  s t imula t ing  effect 
on glycolipids, exemplified in the finding t ha t  it increas- 
ed the levels of cerebroside, lactosylceramide and 
ganglioside GM3 in cultured leukemia cells (16). Bo th  
GlcCer and phorbol  diester  increased interleukin forma- 
tion b y  macrophage  cells (17). 
I t  has been repor ted  tha t  lysosphingolipids are s t rong  
inhibitors of protein kinase C and of phorbol diester bind- 
ing, and the speculation was offered t ha t  the lysolipids 
are responsible for the pathological  features  of sphingo- 
lipidoses such as Gaucher  disease (18). Glucosylsphingo- 
sine does accumulate  in this disorder (albeit to a low con- 
centration) and migh t  be formed to a certain extent  in 
our GlcCer-loaded mice, bu t  one generally cannot  con- 
clude tha t  the inhibition of protein kinase C should lead 
to cell proliferation and increases in enzymes involved in 
D N A  synthesis .  St imulat ion of protein kinase C leads to 
increased levels of ornithine decarboxylase  (12,13), and 
we temporar i ly  could conclude tha t  GlcCer injection pro- 
duces an increase in the kinase, not  an inhibition. 
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COMMUNICATIONS 
In one experiment,  we weighed the mouse spleens and 
found no significant change in weight after  injecting 
GlcCer. The lack of effect can be a t t r ibuted  to  our fin- 
ding of rapid uptake of the exogenous GlcCer by  fiver (3). 
This is consistent with an observation made recently with 
labeled L-glucosylceramide, an unnatural  enantiomer that  
apparent ly  is unmetabolizable (19). 
Omit ted in this preliminary s tudy was a control group 
of mice tha t  had been injected only with detergent,  in- 
stead of saline. Myrj alone had been found to have no ef- 
fect on liver weight (3), and it has been found to be 
replaceable by lecithin for production of GlcCer's growth 
effect (Datta and Radin, unpublished data). Moreover, our 
experiment  with GlcCer/Myrj without  CBE produced a 
smaller increase in thymidine kinase, a result  tha t  is con- 
sistent with the assignment of the effect to the lipid rather 
than to the detergent.  GlcCer has been found to enhance 
the proliferation of Ehrfich ascites carcinoma cells in vivo 
without  the inclusion of detergent  (20). While it  seems 
highly unlikely tha t  the detergent  is responsible for the 
interest ing increases in enzyme act ivi ty  reported here, 
future studies should include a detergent  or lecithin con- 
trol  group. 
We suggest  tha t  GlcCer has mitogenic properties,  act- 
ing through a relatively direct mechanism. I t  may  func- 
tion not  only as a precursor for nearly all the glycofipids 
but also to control organ growth in normal animals. The 
possible roles of GlcCer and/or related glycofipids in cell 
proliferation and cancer have been discussed more fully 
{21). 
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